Although the first-generation RAF inhibitors achieved promising outcomes on treating BRAF(V600E)-harboring cancers, their efficacy is abrogated by quick-rising resistance within a median time of 6-7 months[24-27]. The gene discussed is BRAF; the disease is cancer.